BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+9.6%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$10.2B
AUM Growth
+$10.2B
(+8.4%)
Cap. Flow
+$197M
Cap. Flow
% of AUM
1.92%
Top 10 Holdings %
Top 10 Hldgs %
30.33%
Holding
228
New
12
Increased
78
Reduced
41
Closed
15
Top Buys
| 1 |
Vertex Pharmaceuticals
VRTX
|
$72M |
| 2 |
Tandem Diabetes Care
TNDM
|
$48M |
| 3 |
IQVIA
IQV
|
$42.6M |
| 4 |
Adaptive Biotechnologies
ADPT
|
$39.3M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$39M |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$238M |
| 2 |
Moderna
MRNA
|
$62.9M |
| 3 |
Cigna
CI
|
$45.4M |
| 4 |
Bristol-Myers Squibb
BMY
|
$41.5M |
| 5 |
DaVita
DVA
|
$39.6M |
Sector Composition
| 1 | Healthcare | 96.41% |
| 2 | Industrials | 0.94% |
| 3 | Technology | 0.31% |
| 4 | Financials | 0.04% |
| 5 | Consumer Discretionary | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
DexCom
DXCM
$30.9B
| $105M | 1.02% |
979,104
+114,332
| +13% | +$12.2M |
|
27
Centene
CNC
$14.8B
| $101M | 0.99% |
1,386,297
+95,700
| +7% | +$6.98M |
|
28
Halozyme
HALO
$8.75B
| $101M | 0.99% |
2,224,466
-787,500
| -26% | -$35.8M |
|
29
Boston Scientific
BSX
$159B
| $99.5M | 0.97% |
2,326,787
| – | – |
|
|
30
Tandem Diabetes Care
TNDM
$834M
| $99.4M | 0.97% |
1,020,368
+493,234
| +94% | +$48M |
|
|
SWAV
31
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $98.1M | 0.96% |
516,915
+32,351
| +7% | +$6.14M |
|
|
32
Bristol-Myers Squibb
BMY
$96.7B
| $97.8M | 0.95% |
1,463,432
-621,720
| -30% | -$41.5M |
|
33
Jazz Pharmaceuticals
JAZZ
$7.99B
| $96.8M | 0.94% |
544,750
-5,900
| -1% | -$1.05M |
|
34
Relay Therapeutics
RLAY
$709M
| $96.6M | 0.94% |
2,640,962
+709,618
| +37% | +$26M |
|
35
Align Technology
ALGN
$9.59B
| $95.8M | 0.94% |
156,770
+12,810
| +9% | +$7.83M |
|
36
Esperion Therapeutics
ESPR
$490M
| $95.6M | 0.93% |
4,519,164
+530,000
| +13% | +$11.2M |
|
|
ACCD
37
DELISTED
Accolade, Inc. Common Stock
ACCD
| $93.7M | 0.91% |
1,724,699
+163,578
| +10% | +$8.88M |
|
38
Edwards Lifesciences
EW
$47.7B
| $92.2M | 0.9% |
890,256
| – | – |
|
39
Stryker
SYK
$149B
| $89.5M | 0.87% |
344,514
| – | – |
|
40
Insmed
INSM
$30.3B
| $88.8M | 0.87% |
3,120,901
+643,735
| +26% | +$18.3M |
|
41
Insulet
PODD
$24.2B
| $88.4M | 0.86% |
322,119
-112,069
| -26% | -$30.8M |
|
42
Beam Therapeutics
BEAM
$1.9B
| $78.9M | 0.77% |
612,821
+46,000
| +8% | +$5.92M |
|
43
Evolent Health
EVH
$1.11B
| $76.8M | 0.75% |
3,638,411
+109,864
| +3% | +$2.32M |
|
|
HRC
44
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $76.5M | 0.75% |
673,878
+13,250
| +2% | +$1.51M |
|
|
MTEM
45
DELISTED
Molecular Templates, Inc.
MTEM
| $75.3M | 0.74% |
641,908
+98,701
| +18% | +$11.6M |
|
46
Idexx Laboratories
IDXX
$50.7B
| $74.6M | 0.73% |
118,120
+26,871
| +29% | +$17M |
|
47
Baxter International
BAX
$12.1B
| $72.5M | 0.71% |
900,623
+426,000
| +90% | +$34.3M |
|
48
Inspire Medical Systems
INSP
$2.53B
| $72.1M | 0.7% |
373,226
+53,038
| +17% | +$10.3M |
|
49
Nektar Therapeutics
NKTR
$543M
| $70.4M | 0.69% |
273,427
+9,787
| +4% | +$2.52M |
|
50
ESSA Pharma
EPIX
$11.2M
| $70.3M | 0.69% |
2,459,814
+634,000
| +35% | +$18.1M |
|